Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2019 | Nov. 06, 2019 | |
Document Information [Line Items] | ||
Entity Registrant Name | VIVEVE MEDICAL, INC. | |
Entity Central Index Key | 0000879682 | |
Trading Symbol | vive | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Common Stock, Shares Outstanding (in shares) | 1,477,529 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false | |
Title of 12(b) Security | Common Stock |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2019 | Dec. 31, 2018 | [1] |
Current assets: | |||
Cash and cash equivalents | $ 9,086,000 | $ 29,523,000 | |
Accounts receivable, net of allowance for doubtful accounts of $543 and $284 as of September 30, 2019 and December 31, 2018, respectively | 2,806,000 | 5,704,000 | |
Inventory | 4,141,000 | 4,119,000 | |
Prepaid expenses and other current assets | 3,051,000 | 2,558,000 | |
Total current assets | 19,084,000 | 41,904,000 | |
Property and equipment, net | 3,066,000 | 2,916,000 | |
Investment in limited liability company | 1,412,000 | 1,843,000 | |
Other assets | 587,000 | 171,000 | |
Total assets | 24,149,000 | 46,834,000 | |
Current liabilities: | |||
Accounts payable | 1,791,000 | 3,994,000 | |
Total accrued liabilities | 4,457,000 | 6,766,000 | |
Total current liabilities | 6,248,000 | 10,760,000 | |
Note payable, noncurrent portion | 31,694,000 | 30,528,000 | |
Other noncurrent liabilities | 997,000 | 634,000 | |
Total liabilities | 38,939,000 | 41,922,000 | |
Commitments and contingences (Note 8) | |||
Stockholders’ equity (deficit): | |||
Common stock, $0.0001 par value; 75,000,000 shares authorized as of September 30, 2019 and December 31, 2018; 1,469,789 and 463,630 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively | |||
Additional paid-in capital | 168,304,000 | 160,297,000 | |
Accumulated deficit | (183,094,000) | (155,385,000) | |
Total stockholders’ equity (deficit) | (14,790,000) | 4,912,000 | |
Total liabilities and stockholders’ equity (deficit) | $ 24,149,000 | $ 46,834,000 | |
[1] | The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date. |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 | [1] |
Accounts receivable, allowance for doubtful accounts | $ 543 | $ 284 | |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 | |
Common stock, shares authorized (in shares) | 75,000,000 | 75,000,000 | |
Common stock, shares issued (in shares) | 1,469,789 | 463,630 | |
Common stock, shares outstanding (in shares) | 1,469,789 | 463,630 | |
[1] | The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date. |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Revenue | $ 1,052,000 | $ 4,821,000 | $ 5,116,000 | $ 14,045,000 |
Cost of revenue | 1,099,000 | 3,327,000 | 3,981,000 | 8,390,000 |
Gross profit (loss) | (47,000) | 1,494,000 | 1,135,000 | 5,655,000 |
Operating expenses: | ||||
Research and development | 1,449,000 | 3,442,000 | 6,831,000 | 10,870,000 |
Selling, general and administrative | 5,032,000 | 9,114,000 | 17,188,000 | 27,482,000 |
Restructuring costs | 742,000 | |||
Total operating expenses | 6,481,000 | 12,556,000 | 24,761,000 | 38,352,000 |
Loss from operations | (6,528,000) | (11,062,000) | (23,626,000) | (32,697,000) |
Interest expense, net | (1,209,000) | (1,106,000) | (3,519,000) | (3,239,000) |
Other expense, net | (51,000) | (4,000) | (133,000) | (14,000) |
Net loss from consolidated companies | (7,788,000) | (12,172,000) | (27,278,000) | (35,950,000) |
Loss from minority interest in limited liability company | (168,000) | (132,000) | (431,000) | (539,000) |
Comprehensive and net loss | $ (7,956,000) | $ (12,304,000) | $ (27,709,000) | $ (36,489,000) |
Net loss per share: | ||||
Basic and diluted (in dollars per share) | $ (13.51) | $ (39.07) | $ (54.73) | $ (123.41) |
Weighted average shares used in computing net loss per common share: | ||||
Basic and diluted (in shares) | 588,976 | 314,899 | 506,329 | 295,677 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands | February 2018 Offering [Member]Common Stock [Member] | February 2018 Offering [Member]Additional Paid-in Capital [Member] | February 2018 Offering [Member] | November 2017 ATM Facility [Member]Common Stock [Member] | November 2017 ATM Facility [Member]Additional Paid-in Capital [Member] | November 2017 ATM Facility [Member]Retained Earnings [Member] | November 2017 ATM Facility [Member] | August 2019 ATM Facility [Member]Common Stock [Member] | August 2019 ATM Facility [Member]Additional Paid-in Capital [Member] | August 2019 ATM Facility [Member]Retained Earnings [Member] | August 2019 ATM Facility [Member] | Consultant [Member]Common Stock [Member] | Consultant [Member]Additional Paid-in Capital [Member] | Consultant [Member]Retained Earnings [Member] | Consultant [Member] | Director [Member]Common Stock [Member] | Director [Member]Additional Paid-in Capital [Member] | Director [Member]Retained Earnings [Member] | Director [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total | |
Balances (in shares) at Dec. 31, 2017 | 195,033 | |||||||||||||||||||||||
Balances at Dec. 31, 2017 | $ 102,981 | $ (105,581) | $ (2,600) | |||||||||||||||||||||
Stock-based compensation expense | 645 | 645 | ||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 207 | |||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | 65 | 65 | ||||||||||||||||||||||
Issuance of restricted shares (in shares) | 221 | |||||||||||||||||||||||
Issuance of restricted shares | 108 | 108 | ||||||||||||||||||||||
Net loss | (12,669) | (12,669) | ||||||||||||||||||||||
Stock offering, net of issuance costs (in shares) | 115,000 | 2,082 | ||||||||||||||||||||||
Stock offering, net of issuance costs | $ 32,225 | $ 32,225 | $ 1,011 | $ 1,011 | ||||||||||||||||||||
Cumulative effect adjustment from adoption of new accounting standard – ASC 606 | 177 | 177 | ||||||||||||||||||||||
Balances (in shares) at Mar. 31, 2018 | 312,543 | |||||||||||||||||||||||
Balances at Mar. 31, 2018 | 137,035 | (118,073) | 18,962 | |||||||||||||||||||||
Balances (in shares) at Dec. 31, 2017 | 195,033 | |||||||||||||||||||||||
Balances at Dec. 31, 2017 | 102,981 | (105,581) | (2,600) | |||||||||||||||||||||
Net loss | (36,489) | |||||||||||||||||||||||
Stock offering, net of issuance costs (in shares) | 2,771 | |||||||||||||||||||||||
Balances (in shares) at Sep. 30, 2018 | 315,226 | |||||||||||||||||||||||
Balances at Sep. 30, 2018 | 139,126 | (141,893) | (2,767) | |||||||||||||||||||||
Balances (in shares) at Mar. 31, 2018 | 312,543 | |||||||||||||||||||||||
Balances at Mar. 31, 2018 | 137,035 | (118,073) | 18,962 | |||||||||||||||||||||
Stock-based compensation expense | 709 | 709 | ||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 256 | |||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | 59 | 59 | ||||||||||||||||||||||
Issuance of restricted shares (in shares) | 208 | |||||||||||||||||||||||
Issuance of restricted shares | 67 | 67 | ||||||||||||||||||||||
Issuance of common shares in connection with restricted stock award to employee (in shares) | 1,000 | |||||||||||||||||||||||
Issuance of common shares in connection with restricted stock award to employee | 256 | 256 | ||||||||||||||||||||||
Net loss | (11,516) | (11,516) | ||||||||||||||||||||||
Stock offering, net of issuance costs (in shares) | 652 | |||||||||||||||||||||||
Stock offering, net of issuance costs | 171 | $ 171 | ||||||||||||||||||||||
February 2018 Offering issuance costs | (11) | (11) | ||||||||||||||||||||||
Balances (in shares) at Jun. 30, 2018 | 314,659 | |||||||||||||||||||||||
Balances at Jun. 30, 2018 | 138,286 | (129,589) | 8,697 | |||||||||||||||||||||
Stock-based compensation expense | 698 | 698 | ||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 286 | |||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | 64 | 64 | ||||||||||||||||||||||
Issuance of restricted shares (in shares) | 182 | |||||||||||||||||||||||
Issuance of restricted shares | 47 | 47 | ||||||||||||||||||||||
Issuance of common shares in connection with restricted stock award to employee (in shares) | 62 | |||||||||||||||||||||||
Issuance of common shares in connection with restricted stock award to employee | 20 | 20 | ||||||||||||||||||||||
Net loss | (12,304) | (12,304) | ||||||||||||||||||||||
Stock offering, net of issuance costs (in shares) | 37 | 37 | ||||||||||||||||||||||
Stock offering, net of issuance costs | $ 11 | $ 11 | ||||||||||||||||||||||
Balances (in shares) at Sep. 30, 2018 | 315,226 | |||||||||||||||||||||||
Balances at Sep. 30, 2018 | 139,126 | (141,893) | (2,767) | |||||||||||||||||||||
Balances (in shares) at Dec. 31, 2018 | 463,630 | |||||||||||||||||||||||
Balances at Dec. 31, 2018 | 160,297 | (155,385) | 4,912 | [1] | ||||||||||||||||||||
Stock-based compensation expense | 470 | 470 | ||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 429 | |||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | 35 | 35 | ||||||||||||||||||||||
Issuance of restricted shares (in shares) | 274 | |||||||||||||||||||||||
Issuance of restricted shares | $ 25 | $ 25 | ||||||||||||||||||||||
Issuance of common shares in connection with restricted stock award to employee (in shares) | 6 | |||||||||||||||||||||||
Issuance of common shares in connection with restricted stock award to employee | 1 | 1 | ||||||||||||||||||||||
Net loss | (10,029) | (10,029) | ||||||||||||||||||||||
Balances (in shares) at Mar. 31, 2019 | 464,339 | |||||||||||||||||||||||
Balances at Mar. 31, 2019 | 160,828 | (165,414) | (4,586) | |||||||||||||||||||||
Balances (in shares) at Dec. 31, 2018 | 463,630 | |||||||||||||||||||||||
Balances at Dec. 31, 2018 | 160,297 | (155,385) | 4,912 | [1] | ||||||||||||||||||||
Net loss | (27,709) | |||||||||||||||||||||||
Stock offering, net of issuance costs (in shares) | 0 | |||||||||||||||||||||||
Balances (in shares) at Sep. 30, 2019 | 1,469,789 | |||||||||||||||||||||||
Balances at Sep. 30, 2019 | 168,304 | (183,094) | (14,790) | |||||||||||||||||||||
Balances (in shares) at Mar. 31, 2019 | 464,339 | |||||||||||||||||||||||
Balances at Mar. 31, 2019 | 160,828 | (165,414) | (4,586) | |||||||||||||||||||||
Stock-based compensation expense | 562 | 562 | ||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 602 | |||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | 20 | 20 | ||||||||||||||||||||||
Issuance of restricted shares (in shares) | 250 | 527 | ||||||||||||||||||||||
Issuance of restricted shares | $ 11 | $ 11 | $ 48 | $ 48 | ||||||||||||||||||||
Issuance of common shares in connection with restricted stock award to employee (in shares) | 6 | |||||||||||||||||||||||
Issuance of common shares in connection with restricted stock award to employee | ||||||||||||||||||||||||
Net loss | (9,724) | (9,724) | ||||||||||||||||||||||
Balances (in shares) at Jun. 30, 2019 | 465,724 | |||||||||||||||||||||||
Balances at Jun. 30, 2019 | 161,469 | (175,138) | (13,669) | |||||||||||||||||||||
Stock-based compensation expense | 503 | 503 | ||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 200 | |||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | 1 | 1 | ||||||||||||||||||||||
Issuance of restricted shares (in shares) | 378 | |||||||||||||||||||||||
Issuance of restricted shares | 14 | 14 | ||||||||||||||||||||||
Issuance of common shares in connection with restricted stock award to employee (in shares) | 4 | |||||||||||||||||||||||
Issuance of common shares in connection with restricted stock award to employee | ||||||||||||||||||||||||
Net loss | (7,956) | (7,956) | ||||||||||||||||||||||
Stock offering, net of issuance costs (in shares) | 0 | 1,004,171 | 1,004,171 | |||||||||||||||||||||
Stock offering, net of issuance costs | $ 6,322 | $ 6,322 | ||||||||||||||||||||||
Reverse stock split - cancellation and payout of fractional shares (in shares) | (688) | |||||||||||||||||||||||
Reverse stock split - cancellation and payout of fractional shares | (5) | (5) | ||||||||||||||||||||||
Balances (in shares) at Sep. 30, 2019 | 1,469,789 | |||||||||||||||||||||||
Balances at Sep. 30, 2019 | $ 168,304 | $ (183,094) | $ (14,790) | |||||||||||||||||||||
[1] | The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date. |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | ||
Cash flows from operating activities: | |||
Net loss | $ (27,709,000) | $ (36,489,000) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Provision for doubtful accounts | 260,000 | 103,000 | |
Depreciation and amortization | 819,000 | 545,000 | |
Stock-based compensation | 1,634,000 | 2,294,000 | |
Fair value of common shares issued | 256,000 | ||
Non-cash interest expense | 1,266,000 | 1,176,000 | |
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities | 4,000 | ||
Loss from minority interest in limited liability company | 431,000 | 539,000 | |
Loss on disposal of property and equipment | 93,000 | ||
Changes in assets and liabilities: | |||
Accounts receivable | 2,638,000 | 1,119,000 | |
Inventory | (236,000) | (2,317,000) | |
Prepaid expenses and other current assets | (493,000) | 61,000 | |
Other noncurrent assets | 40,000 | 1,000 | |
Accounts payable | (2,203,000) | (1,297,000) | |
Accrued and other liabilities | (2,566,000) | 502,000 | |
Other noncurrent liabilities | 160,000 | 262,000 | |
Net cash used in operating activities | (25,862,000) | (33,245,000) | |
Cash flows from investing activities: | |||
Purchase of property and equipment | (848,000) | (983,000) | |
Net cash used in investing activities | (848,000) | (983,000) | |
Cash flows from financing activities: | |||
Proceeds from sale of common stock, net of issuance costs | 6,322,000 | 33,407,000 | |
Proceeds from issuance of common shares from employee stock purchase plan | 56,000 | 188,000 | |
Transaction costs in connection with note payable | (100,000) | ||
Reverse stock split - cancellation and payout of fractional shares | (5,000) | ||
Net cash provided by financing activities | 6,273,000 | 33,595,000 | |
Net decrease in cash and cash equivalents | (20,437,000) | (633,000) | |
Cash and cash equivalents - beginning of period | 29,523,000 | [1] | 20,730,000 |
Cash and cash equivalents - end of period | 9,086,000 | 20,097,000 | |
Supplemental disclosure: | |||
Cash paid for interest | 2,067,000 | 1,991,000 | |
Cash paid for income taxes | 2,000 | ||
Supplemental disclosure of cash flow information as of end of period: | |||
Issuance of note payable in settlement of accrued interest | 973,000 | 934,000 | |
Net transfer of equipment between inventory and property and equipment | 214,000 | 210,000 | |
Operating cash outflows from operating leases | 220,000 | ||
Right-of-use assets obtained in exchange for operating lease liabilities (upon adoption of ASC 842) | $ 629,000 | ||
[1] | The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date. |
Note 1 - The Company and Basis
Note 1 - The Company and Basis of Presentation | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency ATM Equity Offerings The Company established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, August 16, 2019, may $6,760,000 “August 2019 $6,760,000 August 2019 September 2019. three September 30, 2019, 1,004,171 August 2019 $6,322,000. September 30, 2019, no August 2019 The Company had previously established an “at-the-market” equity offering program through the filing of a prospectus supplement to its shelf registration statement on Form S- 3, November 8, 2017, $25,000,000 “November 2017 August 16, 2019, November 2017 November 7, 2017. no November 2017 three nine September 30, 2019, zero November 2017 three nine September 30, 2018, 37 2,771 November 2017 $11,000 $1,194,000, November 2017 August 2019, 3,364 $1,318,000. Public Offerings In December 2018, “December 2018 147,285 $22,093,000. $20,385,000. In February 2018, “February 2018 115,000 $34,500,000. $32,214,000. Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2018, March 15, 2019. three nine September 30, 2019 not December 31, 2019 Liquidity and Management Plans The Company has adopted the Financial Accounting Standards Board’s (“FASB”) Accounting Standard Codification (“ASC”) Topic 205 40, one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of September 30, 2019, $183,094,000, $9,086,000 $12,836,000. $6,608,000 three September 30, 2019 $25,862,000 nine September 30, 2019. November 2020. not one To fund further operations, the Company will need to raise additional capital. The Company may no not no no |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Summary of Significant Accounting Policies Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reverse Stock Split On September 18, 2019, 1 100 September 18, 2019. not No The par value of the Company’s common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75 The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company’s equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Changes in Accounting Policies Except for the changes for the adoption of the new accounting standard for leases, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. Adoption of New Accounting Standard - Leases The Company adopted FASB’s Accounting Standards Update (“ASU”) No. 2016 02, 842 January 1, 2019, $629,000 $629,000, January 1, 2019. not not The effect of the changes made to our consolidated January 1, 2019 Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 ( 1 Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. ( 2 Represents recognition of operating lease liabilities. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three September 30, 2019, two 31 three September 30, 2018, three 42% nine September 30, 2019, one 17 nine September 30, 2018, one 21% There were no 10% three nine September 30, 2019 2018. As of September 30, 2019, four 67% December 31, 2018, three 54% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $543,000 September 30, 2019 $284,000 December 31, 2018. Revenue Recognition Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company’s operating leases for the Viveve System have a rental period of six June 30, 2019 not September 30, 2019, $579,000 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered nonlease components. In the contracts with lease and nonlease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No September 30, 2019 December 31, 2018. $470,000, not September 30, 2019 $686,000 December 31, 2018. The following table reflects the changes in our customer contract liabilities for the nine September 30, 2019: September 30, December 31, Nine Months 2019 2018 Change Customer contracts liabilities: Marketing programs $ 470 $ 639 $ (169 ) Other - 47 (47 ) Total $ 470 $ 686 $ (216 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three nine September 30, 2019 2018, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract costs in the amount of $198,000 $0 September 30, 2019 2018, three nine September 30, 2019, $30,000 $0 2018 no six Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three nine September 30, 2019 2018 Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 North America $ 652 $ 3,455 $ 3,106 $ 10,613 Asia Pacific 373 717 1,684 2,238 Europe and Middle East 27 612 316 1,143 Latin America - 37 10 51 Total $ 1,052 $ 4,821 $ 5,116 $ 14,045 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three nine September 30, 2019 2018. Product Warranty The Company’s products are generally subject to warranties between one three not Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three nine September 30, 2019 2018, Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Nine Months Ended September 30, 2019 2018 Stock options to purchase common stock 50,471 42,917 Warrants to purchase common stock 5,549 6,408 Restricted common stock awards 3,432 600 Other Recently Issued and Adopted Accounting Standards In June 2018, 2018 07, 718 718 718 December 15, 2018, January 1, 2019 not We have reviewed other recent accounting pronouncements and concluded they are either not no |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurements | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no September 30, 2019 December 31, 2018. The carrying amounts of the Company’s financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of September 30, 2019, December 31, 2018 There were no |
Note 4 - Investment in Limited
Note 4 - Investment in Limited Liability Company | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | 4. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not September 30, 2019, 4,800 zero $27,000 three nine September 30, 2019 no September 30, 2019 December 31, 2018. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not September 30, 2019, 7% three three nine September 30, 2019, $168,000 $431,000, three nine September 30, 2018, $132,000 $539,000, In February 2019, no |
Note 5 - Accrued Liabilities
Note 5 - Accrued Liabilities | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 5. Accrued Liabilities Accrued liabilities consisted of the following as of September 30, 2019 December 31, 2018 ( September 30, December 31, 2019 2018 Accrued bonuses $ 728 $ 837 Accrued interest 704 683 Deferred revenue - subscription rental program 579 - Accrued payroll and other related expenses 500 877 Accrued professional fees 494 978 Customer contracts liabilities 470 686 Accrued sales commission 423 1,743 Current operating lease liabilities 257 - Accrued clinical trial costs 166 84 Travel and entertainment 54 280 Accrued sales & use tax 9 259 Other accruals 73 339 Total accrued liabilities $ 4,457 $ 6,766 |
Note 6 - Note Payable
Note 6 - Note Payable | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 6. Note Payable On May 22, 2017, “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 A portion of the initial loan proceeds were used to repay all of the amounts owed by the Company under its 2016 2017 may The 2017 six four 2017 12.5%, 4.0% may, three nine September 30, 2019, $331,000 $973,000, three nine September 30, 2018, $318,000 $934,000, 5.0% September 30, 2019, $756,000 The Company may 2017 first five no As security for its obligations under the 2017 The terms of the 2017 $2.0 2022, not 2.0 2017 September 30, 2019, As of September 30, 2019 December 31, 2018, $31,694,000 $30,528,000, 2017 In connection with the 2017 two 10 2,220 $950.00 9 As of September 30, 2019, Year Ending December 31, 2019 (remaining three months) $ 710 2020 2,901 2021 16,673 2022 19,306 2023 6,220 Total payments 45,810 Less: Amount representing interest (13,087 ) Present value of obligations 32,723 Less: Unamortized debt discount (1,029 ) Note payable, noncurrent portion $ 31,694 |
Note 7 - Leases
Note 7 - Leases | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 7. Leases Lessee: The following information pertains to those operating lease agreements where the Company is the lessee. In January 2012, March 2012 April 2018. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2020. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 Rent expense for the three nine September 30, 2018 $65,000 $293,000. In September 2018, 36 September 20, 2018. $3,000. After the adoption of ASU 842 January 1, 2019, 12 not The following table reflects the Company's lease assets and lease liabilities at September 30, 2019 January 1, 2019 ( September 30, January 1, 2019 2019 Assets: Operating lease right-of-use assets $ 456 $ 629 Liabilities: Current operating lease liabilities $ 257 $ 230 Noncurrent operating lease liabilities 203 399 $ 460 $ 629 The operating lease right-of-use assets are included in other assets on the condensed consolidated balance sheet. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the condensed consolidated balance sheet. The operating leases expense for the three nine September 30, 2019 $75,000 $225,000, As of September 30, 2019, Year Ending December 31, 2019 (remaining three months) $ 75 2020 303 2021 136 Total lease payments 514 Less: Amount representing interest (54 ) Present value of lease liabilities $ 460 The weighted average remaining lease term was approximately 20 September 30, 2019. three nine September 30, 2019 12.5%. Lessor: The following information pertains to those operating lease agreements where the Company is the lessor. As of September 30, 2019, Year Ending December 31, 2019 (remaining three months) $ 255 2020 324 Thereafter - Total $ 579 As of September 30, 2019, $456,000 three nine September 30, 2019 $46,000 $46,000, |
Note 8 - Commitments and Contin
Note 8 - Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 8. Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not |
Note 9 - Common Stock
Note 9 - Common Stock | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 9. Common Stock Through the August 2019 may $6,760,000 $6,760,000 August 2019 September 2019. three September 30, 2019, 1,004,171 August 2019 $6,322,000. In August 2019, November 2017 $25,000,000 three nine September 30, 2019, zero November 2017 three nine September 30, 2018, 37 2,771 November 2017 $11,000 $1,194,000, November 2017 August 2019, 3,364 $1,318,000. In March 2019, 274 $25,000. In December 2018, December 2018 147,285 $22,093,000. $20,385,000. In June 2018, 1,000 $256,000. In February 2018, February 2018 115,000 $34,500,000. $32,214,000. Warrants for Common Stock As of September 30, 2019, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants October 2014 Common Shares October 13, 2019 $ 424.00 288 November 2014 Common Shares November 12, 2019 $ 424.00 125 February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 May 2015 Common Shares May 17, 2020 $ 424.00 215 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 5,549 In connection with the 2017 2,220, $950.00 ten $940,000 0%, 55.1%, 2.25% ten $790,000, three nine September 30, 2019, $92,000 $270,000, three nine September 30, 2018, $82,000 $242,000, No three nine September 30, 2019 2018. No three nine September 30, 2019 2018. A total of 859 three nine September 30, 2019. No three nine September 30, 2018. |
Note 10 - Summary of Stock Opti
Note 10 - Summary of Stock Options | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 10. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards (“RSAs”) from two 2006 “2006 2013 “2013 As of September 30, 2019, 2006 104 no $992.00 3.3 As of September 30, 2019, 2013 50,367 11,770 $297.56 8.3 In January 2019, 2019 2013 20,431 49,140 69,571 January 1, 2019. In September 2019, 2013 18% 1 $5.0 2 December 31, 2019. Activity under the 2006 2013 Nine Months Ended September 30, 2019 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 40,144 $ 456.00 7.4 $ - Options granted 23,344 $ 117.91 Options exercised - Options canceled (13,017 ) $ 457.34 Options outstanding, end of period 50,471 $ 298.99 8.3 $ - Vested and exercisable and expected to vest, end of period 48,506 $ 302.18 8.3 $ - Vested and exercisable, end of period 21,169 $ 397.45 7.4 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company’s closing share price as of September 30, 2019. The options outstanding and exercisable as of September 30, 2019 Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices September 30, 2019 Price Term (Years) September 30, 2019 Price $38.00 - $58.00 1,650 $ 55.42 9.7 - $ - $100.00 - $197.00 25,496 $ 138.25 9.1 6,839 $ 148.08 $202.00 - $283.00 775 $ 252.06 8.3 305 $ 258.36 $311.00 - $382.00 4,377 $ 357.96 8.1 2,318 $ 360.44 $430.00 - $497.00 8,908 $ 452.58 7.7 4,576 $ 454.70 $501.00 - $567.00 4,594 $ 536.63 6.9 3,126 $ 536.17 $600.00 - $661.00 2,397 $ 601.91 5.9 2,236 $ 601.42 $700.00 - $792.00 2,170 $ 769.23 6.3 1,665 $ 769.86 $992.00 - $992.00 104 $ 992.00 3.3 104 $ 992.00 Total: 50,471 $ 298.99 8.3 21,169 $ 397.45 Restricted Stock Awards (‘RSA”) In July 2019, 378 2013 $38.08 378 In June 2019, 250 June 2018. In April 2019, 525 2013 $91.00 525 In January 2019, 3,625 2013 2018 2018 50% 50% three nine September 30, 2019, 421 443 September 30, 2019, zero As of September 30, 2019, 3,432 2017 The eighth 2017 “2017 July 1, 2019 September 30, 2019, 200 September 30, 2019 $3.75. The seventh 2017 April 1, 2019 June 30, 2019, 602 June 28, 2019 $32.30. The sixth 2017 January 1, 2019 March 31, 2019, 429 March 29, 2019 $79.88. As of September 30, 2019, 2017 1,392 The Company estimates the fair value of purchase rights under the ESPP using a Black-Scholes valuation model. The fair value of each purchase right was estimated on the date of grant using the Black-Scholes option valuation model and the straight-line attribution approach with the following weighted-average assumptions: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (in years) 0.25 0.25 0.25 0.25 Average volatility 98 % 67 % 84 % 67 % Risk-free interest rate 2.21 % 1.93 % 2.40 % 1.71 % Dividend yield 0 % 0 % 0 % 0 % The weighted average grant date fair value of the purchase rights issued under the 2017 three nine September 30, 2019 $13.16 $2.12, three nine September 30, 2018 $75.00 $100.00, Stock-Based Compensation During the three September 30, 2019, not three September 30, 2018, 2,375 $301.17 nine September 30, 2019 2018, 23,069 20,544 $117.86 $364.98 no three nine September 30, 2019 2018. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (in years) N/A 5 5 5 Average volatility N/A 70 % 73 % 73 % Risk-free interest rate N/A 2.86 % 2.49 % 2.67 % Dividend yield N/A 0 % 0 % 0 % During the three September 30, 2019, not nine September 30, 2019, 275 $121.82. three nine September 30, 2018, 100 2,123 $283.00 $241.69 no three nine September 30, 2019 2018. The fair value of nonemployee stock options granted was estimated using the following weighted average assumptions: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (in years) N/A 10 5 10 Average volatility N/A 66 % 73 % 66 % Risk-free interest rate N/A 3.04 % 2.49 % 3.04 % Dividend yield N/A 0 % 0 % 0 % Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company’s stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies’ stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of employee stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three nine September 30, 2019 2018 Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Cost of revenue $ 25 $ 19 $ 91 $ 47 Research and development 41 79 134 266 Selling, general and administrative 451 667 1,409 1,981 Total $ 517 $ 765 $ 1,634 $ 2,294 As of September 30, 2019, $3,371,000. 2.2 |
Note 11 - Income Taxes
Note 11 - Income Taxes | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 11. Income Taxes No no For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company’s effective tax rate is 0% three nine September 30, 2019. 2019 0%. |
Note 12 - Related Party Transac
Note 12 - Related Party Transactions | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 12. Related Party Transactions In June 2006, October 4, 2007. 300 September 30, 2019, 855 375 $720,000 $3,015,000 three September 30, 2019 2018, $3,853,000 $8,613,000 nine September 30, 2019 2018, September 30, 2019 December 31, 2018 456,000 $960,000, |
Note 13 - Restructuring Costs
Note 13 - Restructuring Costs | 9 Months Ended |
Sep. 30, 2019 | |
Notes to Financial Statements | |
Restructuring and Related Activities Disclosure [Text Block] | 13. Restructuring Costs In January 2019, 40 $742,000 September 30, 2019, first 2019 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2019 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. |
Reserve Stock Split, Policy [Policy Text Block] | Reverse Stock Split On September 18, 2019, 1 100 September 18, 2019. not No The par value of the Company’s common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75 The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company’s equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may |
Changes in Accounting Policies, Policy [Policy Text Block] | Changes in Accounting Policies Except for the changes for the adoption of the new accounting standard for leases, the Company has consistently applied the accounting policies to all periods presented in these condensed consolidated financial statements. Adoption of New Accounting Standard - Leases The Company adopted FASB’s Accounting Standards Update (“ASU”) No. 2016 02, 842 January 1, 2019, $629,000 $629,000, January 1, 2019. not not The effect of the changes made to our consolidated January 1, 2019 Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 ( 1 Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. ( 2 Represents recognition of operating lease liabilities. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company’s products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three September 30, 2019, two 31 three September 30, 2018, three 42% nine September 30, 2019, one 17 nine September 30, 2018, one 21% There were no 10% three nine September 30, 2019 2018. As of September 30, 2019, four 67% December 31, 2018, three 54% |
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] | Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $543,000 September 30, 2019 $284,000 December 31, 2018. |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company’s operating leases for the Viveve System have a rental period of six June 30, 2019 not In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered nonlease components. In the contracts with lease and nonlease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No September 30, 2019 December 31, 2018. $470,000, not September 30, 2019 $686,000 December 31, 2018. The following table reflects the changes in our customer contract liabilities for the nine September 30, 2019: September 30, December 31, Nine Months 2019 2018 Change Customer contracts liabilities: Marketing programs $ 470 $ 639 $ (169 ) Other - 47 (47 ) Total $ 470 $ 686 $ (216 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three nine September 30, 2019 2018, not Contract Costs The Company expects that commissions paid to obtain subscriptions are recoverable and has therefore capitalized them as a contract costs in the amount of $198,000 $0 September 30, 2019 2018, three nine September 30, 2019, $30,000 $0 2018 no six Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company’s financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three nine September 30, 2019 2018 Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 North America $ 652 $ 3,455 $ 3,106 $ 10,613 Asia Pacific 373 717 1,684 2,238 Europe and Middle East 27 612 316 1,143 Latin America - 37 10 51 Total $ 1,052 $ 4,821 $ 5,116 $ 14,045 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. |
Equity Method Investments [Policy Text Block] | Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee’s business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three nine September 30, 2019 2018. |
Standard Product Warranty, Policy [Policy Text Block] | Product Warranty The Company’s products are generally subject to warranties between one three not |
Share-based Payment Arrangement [Policy Text Block] | Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee’s service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option’s expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded at their fair value on the measurement date and are subject to periodic adjustment as the underlying equity instruments vest. |
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three nine September 30, 2019 2018, |
Earnings Per Share, Policy [Policy Text Block] | Net Loss per Share The Company’s basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. Nine Months Ended September 30, 2019 2018 Stock options to purchase common stock 50,471 42,917 Warrants to purchase common stock 5,549 6,408 Restricted common stock awards 3,432 600 |
New Accounting Pronouncements, Policy [Policy Text Block] | Other Recently Issued and Adopted Accounting Standards In June 2018, 2018 07, 718 718 718 December 15, 2018, January 1, 2019 not We have reviewed other recent accounting pronouncements and concluded they are either not no |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Cumulative Effect of Adjustments for New Accounting Pronouncements on Balance Sheet [Table Text Block] | Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 |
Contract with Customer, Asset and Liability [Table Text Block] | September 30, December 31, Nine Months 2019 2018 Change Customer contracts liabilities: Marketing programs $ 470 $ 639 $ (169 ) Other - 47 (47 ) Total $ 470 $ 686 $ (216 ) |
Revenue from External Customers by Geographic Areas [Table Text Block] | Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 North America $ 652 $ 3,455 $ 3,106 $ 10,613 Asia Pacific 373 717 1,684 2,238 Europe and Middle East 27 612 316 1,143 Latin America - 37 10 51 Total $ 1,052 $ 4,821 $ 5,116 $ 14,045 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Nine Months Ended September 30, 2019 2018 Stock options to purchase common stock 50,471 42,917 Warrants to purchase common stock 5,549 6,408 Restricted common stock awards 3,432 600 |
Note 5 - Accrued Liabilities (T
Note 5 - Accrued Liabilities (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | September 30, December 31, 2019 2018 Accrued bonuses $ 728 $ 837 Accrued interest 704 683 Deferred revenue - subscription rental program 579 - Accrued payroll and other related expenses 500 877 Accrued professional fees 494 978 Customer contracts liabilities 470 686 Accrued sales commission 423 1,743 Current operating lease liabilities 257 - Accrued clinical trial costs 166 84 Travel and entertainment 54 280 Accrued sales & use tax 9 259 Other accruals 73 339 Total accrued liabilities $ 4,457 $ 6,766 |
Note 6 - Note Payable (Tables)
Note 6 - Note Payable (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | Year Ending December 31, 2019 (remaining three months) $ 710 2020 2,901 2021 16,673 2022 19,306 2023 6,220 Total payments 45,810 Less: Amount representing interest (13,087 ) Present value of obligations 32,723 Less: Unamortized debt discount (1,029 ) Note payable, noncurrent portion $ 31,694 |
Note 7 - Leases (Tables)
Note 7 - Leases (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Lessee, Lease Assets and Liabilities [Table Text Block] | September 30, January 1, 2019 2019 Assets: Operating lease right-of-use assets $ 456 $ 629 Liabilities: Current operating lease liabilities $ 257 $ 230 Noncurrent operating lease liabilities 203 399 $ 460 $ 629 |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Year Ending December 31, 2019 (remaining three months) $ 75 2020 303 2021 136 Total lease payments 514 Less: Amount representing interest (54 ) Present value of lease liabilities $ 460 |
Lessor, Operating Lease, Payments to be Received, Maturity [Table Text Block] | Year Ending December 31, 2019 (remaining three months) $ 255 2020 324 Thereafter - Total $ 579 |
Note 9 - Common Stock (Tables)
Note 9 - Common Stock (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants October 2014 Common Shares October 13, 2019 $ 424.00 288 November 2014 Common Shares November 12, 2019 $ 424.00 125 February 2015 Common Shares February 17, 2025 $ 400.00 754 March 2015 Common Shares March 26, 2025 $ 272.00 14 May 2015 Common Shares May 12, 2025 $ 424.00 362 May 2015 Common Shares May 17, 2020 $ 424.00 215 December 2015 Common Shares December 16, 2025 $ 560.00 267 April 2016 Common Shares April 1, 2026 $ 608.00 250 May 2016 Common Shares May 11, 2021 $ 774.00 50 June 2016 Common Shares June 20, 2026 $ 498.00 1,004 May 2017 Common Shares May 25, 2027 $ 950.00 2,220 5,549 |
Note 10 - Summary of Stock Op_2
Note 10 - Summary of Stock Options (Tables) | 9 Months Ended |
Sep. 30, 2019 | |
Notes Tables | |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Nine Months Ended September 30, 2019 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 40,144 $ 456.00 7.4 $ - Options granted 23,344 $ 117.91 Options exercised - Options canceled (13,017 ) $ 457.34 Options outstanding, end of period 50,471 $ 298.99 8.3 $ - Vested and exercisable and expected to vest, end of period 48,506 $ 302.18 8.3 $ - Vested and exercisable, end of period 21,169 $ 397.45 7.4 $ - |
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] | Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices September 30, 2019 Price Term (Years) September 30, 2019 Price $38.00 - $58.00 1,650 $ 55.42 9.7 - $ - $100.00 - $197.00 25,496 $ 138.25 9.1 6,839 $ 148.08 $202.00 - $283.00 775 $ 252.06 8.3 305 $ 258.36 $311.00 - $382.00 4,377 $ 357.96 8.1 2,318 $ 360.44 $430.00 - $497.00 8,908 $ 452.58 7.7 4,576 $ 454.70 $501.00 - $567.00 4,594 $ 536.63 6.9 3,126 $ 536.17 $600.00 - $661.00 2,397 $ 601.91 5.9 2,236 $ 601.42 $700.00 - $792.00 2,170 $ 769.23 6.3 1,665 $ 769.86 $992.00 - $992.00 104 $ 992.00 3.3 104 $ 992.00 Total: 50,471 $ 298.99 8.3 21,169 $ 397.45 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (in years) N/A 5 5 5 Average volatility N/A 70 % 73 % 73 % Risk-free interest rate N/A 2.86 % 2.49 % 2.67 % Dividend yield N/A 0 % 0 % 0 % Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (in years) N/A 10 5 10 Average volatility N/A 66 % 73 % 66 % Risk-free interest rate N/A 3.04 % 2.49 % 3.04 % Dividend yield N/A 0 % 0 % 0 % |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Cost of revenue $ 25 $ 19 $ 91 $ 47 Research and development 41 79 134 266 Selling, general and administrative 451 667 1,409 1,981 Total $ 517 $ 765 $ 1,634 $ 2,294 |
2017 Employee Stock Purchase Plan [Member] | |
Notes Tables | |
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] | Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Expected term (in years) 0.25 0.25 0.25 0.25 Average volatility 98 % 67 % 84 % 67 % Risk-free interest rate 2.21 % 1.93 % 2.40 % 1.71 % Dividend yield 0 % 0 % 0 % 0 % |
Note 1 - The Company and Basi_2
Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($) | Aug. 16, 2019 | Feb. 12, 2018 | Nov. 08, 2017 | Aug. 31, 2019 | Dec. 31, 2018 | Feb. 28, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2017 | |
Proceeds from Issuance of Common Stock | $ 6,322,000 | $ 33,407,000 | ||||||||||
Retained Earnings (Accumulated Deficit), Ending Balance | $ (155,385,000) | [1] | $ (183,094,000) | (183,094,000) | ||||||||
Cash and Cash Equivalents, at Carrying Value, Ending Balance | $ 29,523,000 | [1] | 9,086,000 | $ 20,097,000 | 9,086,000 | 20,097,000 | $ 20,730,000 | |||||
Working Capital | 12,836,000 | 12,836,000 | ||||||||||
Net Cash Provided by (Used in) Operating Activities, Total | $ (6,608,000) | $ (25,862,000) | $ (33,245,000) | |||||||||
August 2019 ATM Facility [Member] | ||||||||||||
Aggregate Offering Price | $ 6,760,000 | $ 6,760,000 | ||||||||||
Stock Issued During Period, Shares, New Issues | 1,004,171 | |||||||||||
Proceeds From Issuance of Common Stock, Net | $ 6,322,000 | |||||||||||
November 2017 ATM Facility [Member] | ||||||||||||
Aggregate Offering Price | $ 25,000,000 | $ 25,000,000 | ||||||||||
Stock Issued During Period, Shares, New Issues | 3,364 | 0 | 37 | 0 | 2,771 | |||||||
Proceeds From Issuance of Common Stock, Net | $ 1,318,000 | $ 11,000 | $ 11,000 | $ 1,194,000 | $ 1,194,000 | |||||||
December 2018 Offering [Member] | ||||||||||||
Stock Issued During Period, Shares, New Issues | 147,285 | |||||||||||
Proceeds From Issuance of Common Stock, Net | $ 20,385,000 | |||||||||||
Proceeds from Issuance of Common Stock | $ 22,093,000 | |||||||||||
February 2018 Offering [Member] | ||||||||||||
Stock Issued During Period, Shares, New Issues | 115,000 | |||||||||||
Proceeds From Issuance of Common Stock, Net | $ 32,214,000 | $ 32,214,000 | ||||||||||
Proceeds from Issuance of Common Stock | $ 34,500,000 | $ 34,500,000 | ||||||||||
[1] | The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date. |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) | Sep. 18, 2019 | Sep. 30, 2019USD ($)$ / sharesshares | Sep. 30, 2018USD ($) | Jun. 30, 2019 | Sep. 30, 2019USD ($)$ / sharesshares | Sep. 30, 2018USD ($) | Dec. 31, 2018USD ($)$ / sharesshares | Jan. 01, 2019USD ($) | |
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | [1] | |||||
Common Stock, Shares Authorized | shares | 75,000,000 | 75,000,000 | 75,000,000 | [1] | |||||
Operating Lease, Right-of-Use Asset | $ 456,000 | $ 456,000 | $ 629,000 | ||||||
Operating Lease, Liability, Total | $ 460,000 | $ 460,000 | $ 629,000 | ||||||
Number of Financial Institutions | 1 | 1 | |||||||
Accounts Receivable, Allowance for Credit Loss, Ending Balance | $ 543,000 | $ 543,000 | $ 284,000 | ||||||
Deferred Income | 579,000 | 579,000 | |||||||
Contract with Customer, Asset, after Allowance for Credit Loss, Total | 0 | 0 | 0 | ||||||
Contract with Customer, Liability, Total | 470,000 | 470,000 | $ 686,000 | ||||||
Capitalized Contract Cost, Net, Total | 198,000 | $ 0 | 198,000 | $ 0 | |||||
Capitalized Contract Cost, Amortization | 30,000 | 0 | 30,000 | 0 | |||||
Equity Method Investment, Other than Temporary Impairment | $ 0 | $ 0 | $ 0 | $ 0 | |||||
Minimum [Member] | |||||||||
Warranty Period | 1 year | ||||||||
Maximum [Member] | |||||||||
Warranty Period | 3 years | ||||||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | |||||||||
Concentration Risk, Number of Customers | 2 | 3 | 1 | 1 | |||||
Concentration Risk, Percentage | 42.00% | ||||||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member] | |||||||||
Concentration Risk, Percentage | 17.00% | 21.00% | |||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | |||||||||
Concentration Risk, Number of Customers | 4 | 3 | |||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Four Customers [Member] | |||||||||
Concentration Risk, Percentage | 67.00% | ||||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member] | |||||||||
Concentration Risk, Percentage | 54.00% | ||||||||
Reverse Stock Split [Member] | |||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 100 | ||||||||
[1] | The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date. |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Cumulative Effect of Adjustments for New Accounting Pronouncements on Consolidated Balance Sheet (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Jan. 01, 2019 | Dec. 31, 2018 | [1] | |
Other assets | $ 587 | $ 800 | $ 171 | ||
Total assets | 24,149 | 47,463 | 46,834 | ||
Total accrued liabilities | 4,457 | 6,996 | 6,766 | ||
Total current liabilities | 6,248 | 10,990 | 10,760 | ||
Other noncurrent liabilities | 997 | 1,033 | 634 | ||
Total liabilities | 38,939 | 42,551 | 41,922 | ||
Total liabilities and stockholders' equity | $ 24,149 | 47,463 | $ 46,834 | ||
Accounting Standards Update 2016-02 [Member] | |||||
Other assets | [2] | 629 | |||
Total assets | [2] | 629 | |||
Total accrued liabilities | [3] | 230 | |||
Total current liabilities | [3] | 230 | |||
Other noncurrent liabilities | [3] | 399 | |||
Total liabilities | [3] | 629 | |||
Total liabilities and stockholders' equity | [3] | $ 629 | |||
[1] | The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date. | ||||
[2] | Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. | ||||
[3] | Represents recognition of operating lease liabilities. |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Customer Contract Liabilities (Details) - USD ($) | 9 Months Ended | |
Sep. 30, 2019 | Dec. 31, 2018 | |
Customer contract liabilities | $ 470,000 | $ 686,000 |
Change in customer contract liabilities | (216,000) | |
Marketing Programs [Member] | ||
Customer contract liabilities | 470,000 | 639,000 |
Change in customer contract liabilities | (169,000) | |
Product and Service, Other [Member] | ||
Customer contract liabilities | $ 47,000 | |
Change in customer contract liabilities | $ (47,000) |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Revenue | $ 1,052 | $ 4,821 | $ 5,116 | $ 14,045 |
North America [Member] | ||||
Revenue | 652 | 3,455 | 3,106 | 10,613 |
Asia Pacific [Member] | ||||
Revenue | 373 | 717 | 1,684 | 2,238 |
Europe And Middle East [Member] | ||||
Revenue | 27 | 612 | 316 | 1,143 |
Latin America [Member] | ||||
Revenue | $ 37 | $ 10 | $ 51 |
Note 2 - Summary of Significa_7
Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares | 9 Months Ended | |
Sep. 30, 2019 | Sep. 30, 2018 | |
Share-based Payment Arrangement, Option [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 50,471 | 42,917 |
Common Stock Warrants [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 5,549 | 6,408 |
Restricted Stock [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 3,432 | 600 |
Note 4 - Investment in Limite_2
Note 4 - Investment in Limited Liability Company (Details Textual) | Aug. 08, 2017USD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2018USD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2018USD ($) | Dec. 31, 2018USD ($) |
Income (Loss) from Equity Method Investments, Total | $ (168,000) | $ (132,000) | $ (431,000) | $ (539,000) | ||
Membership Unit Subscription Agreement [Member] | InControl Medical [Member] | ||||||
Accounts Payable, Related Parties, Current | $ 0 | $ 0 | $ 0 | |||
InControl Medical [Member] | ||||||
Equity Method Investment, Ownership Percentage | 7.00% | 7.00% | ||||
Income (Loss) from Equity Method Investments, Total | $ (168,000) | $ (132,000) | $ (431,000) | $ (539,000) | ||
InControl Medical [Member] | Membership Unit Subscription Agreement [Member] | ||||||
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased | 4,800 | |||||
Payments for Purchase of Products | $ 0 | $ 27,000 | ||||
Payments to Acquire Equity Method Investments | $ 2,500,000 |
Note 5 - Accrued Liabilities -
Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Jan. 01, 2019 | Dec. 31, 2018 | |
Accrued bonuses | $ 728 | $ 837 | ||
Accrued interest | 704 | 683 | ||
Deferred revenue - subscription rental program | 579 | |||
Accrued payroll and other related expenses | 500 | 877 | ||
Accrued professional fees | 494 | 978 | ||
Customer contracts liabilities | 470 | 686 | ||
Accrued sales commission | 423 | 1,743 | ||
Current operating lease liabilities | 257 | $ 230 | ||
Accrued clinical trial costs | 166 | 84 | ||
Travel and entertainment | 54 | 280 | ||
Accrued sales & use tax | 9 | 259 | ||
Other accruals | 73 | 339 | ||
Total accrued liabilities | $ 4,457 | $ 6,996 | $ 6,766 | [1] |
[1] | The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date. |
Note 6 - Note Payable (Details
Note 6 - Note Payable (Details Textual) - USD ($) | Dec. 29, 2017 | May 22, 2017 | Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 | |
Interest Payable | $ 13,087,000 | $ 13,087,000 | ||||||
Notes Payable, Noncurrent, Total | $ 31,694,000 | $ 31,694,000 | $ 30,528,000 | [1] | ||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 5,549 | 5,549 | ||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | ||||||||
Warrants and Rights Outstanding, Term | 10 years | |||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 2,220 | 2,220 | 2,220 | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 950 | $ 950 | $ 950 | |||||
The 2017 Loan Agreement [Member] | CRG LP [Member] | ||||||||
Debt Instrument, Face Amount | $ 20,000,000 | |||||||
Debt Agreement, Covenant, Additional Funding | 10,000,000 | |||||||
Debt Agreement, Maximum Borrowing Capacity | $ 30,000,000 | |||||||
Proceeds from Lines of Credit, Total | $ 10,000,000 | |||||||
Debt Instrument, Term | 6 years | |||||||
Debt instrument, Interest Only Payment, Period | 4 years | |||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.50% | |||||||
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period | 4.00% | |||||||
Paid-in-Kind Interest | $ 331,000 | $ 318,000 | $ 973,000 | $ 934,000 | ||||
Debt Instrument, Prepayment Fee, Percentage | 5.00% | |||||||
Debt Instrument, Prepayment Fee, Period of Term | 5 years | |||||||
Debt Instrument, Covenant, Cash and Cash Equivalents | $ 2,000,000 | |||||||
Notes Payable, Noncurrent, Total | 31,694,000 | 31,694,000 | $ 30,528,000 | |||||
The 2017 Loan Agreement [Member] | CRG LP [Member] | Other Noncurrent Liabilities [Member] | ||||||||
Interest Payable | $ 756,000 | $ 756,000 | ||||||
[1] | The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date. |
Note 6 - Note Payable - Summary
Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($) $ in Thousands | Sep. 30, 2019 | Dec. 31, 2018 | [1] |
2019 (remaining three months) | $ 710 | ||
2020 | 2,901 | ||
2021 | 16,673 | ||
2022 | 19,306 | ||
2023 | 6,220 | ||
Total payments | 45,810 | ||
Less: Amount representing interest | (13,087) | ||
Present value of obligations | 32,723 | ||
Less: Unamortized debt discount | (1,029) | ||
Note payable, noncurrent portion | $ 31,694 | $ 30,528 | |
[1] | The condensed consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date. |
Note 7 - Leases (Details Textua
Note 7 - Leases (Details Textual) | 1 Months Ended | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2018USD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2018USD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2018USD ($) | Feb. 01, 2017USD ($)ft² | |
Operating Leases, Rent Expense, Total | $ 65,000 | $ 293,000 | ||||
Operating Lease, Cost | $ 75,000 | $ 225,000 | ||||
Operating Lease, Weighted Average Discount Rate, Percent | 12.50% | 12.50% | ||||
Sublease Agreement for Relocation of Headquarters [Member] | ||||||
Area of Real Estate Property | ft² | 12,400 | |||||
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year | 20.5 | |||||
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year | 21.12 | |||||
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year | 21.75 | |||||
Security Deposit | $ 22,000 | |||||
Operating Leases, Allowance for Certain Improvements | $ 88,000 | |||||
Noncancelable Operating Lease Agreement for Office Equipment [Member] | ||||||
Lessee, Operating Lease, Term of Contract | 3 years | 3 years | 3 years | |||
Operating Leases, Monthly Payment | $ 3,000 | |||||
Leases of Viveve Systems [Member] | ||||||
Operating Lease, Property Plant and Equipment, Amount | $ 456,000 | $ 456,000 | ||||
Lessor, Operating Lease, Depreciation on Leased Assets | $ 46,000 | $ 46,000 |
Note 7 - Leases - Lease Assets
Note 7 - Leases - Lease Assets and Liabilities (Details) - USD ($) | Sep. 30, 2019 | Jan. 01, 2019 | Dec. 31, 2018 |
Operating Lease, Right-of-Use Asset | $ 456,000 | $ 629,000 | |
Current operating lease liabilities | 257,000 | 230,000 | |
Noncurrent operating lease liabilities | 203,000 | 399,000 | |
$ 460,000 | $ 629,000 |
Note 7 - Leases - Maturity of O
Note 7 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($) | Sep. 30, 2019 | Jan. 01, 2019 |
2019 (remaining three months) | $ 75,000 | |
2020 | 303,000 | |
2021 | 136,000 | |
Total lease payments | 514,000 | |
Less: Amount representing interest | (54,000) | |
Present value of lease liabilities | $ 460,000 | $ 629,000 |
Note 7 - Leases - Minimum Futur
Note 7 - Leases - Minimum Future Rentals (Details) $ in Thousands | Sep. 30, 2019USD ($) |
2019 (remaining three months) | $ 255 |
2020 | 324 |
Thereafter | |
Total | $ 579 |
Note 9 - Common Stock (Details
Note 9 - Common Stock (Details Textual) | Aug. 16, 2019USD ($) | Feb. 12, 2018USD ($) | Nov. 08, 2017USD ($) | Aug. 31, 2019USD ($)shares | Mar. 31, 2019USD ($) | Dec. 31, 2018USD ($)shares | Jun. 30, 2018USD ($)shares | Feb. 28, 2018USD ($)shares | Sep. 30, 2019USD ($)$ / sharesshares | Sep. 30, 2018USD ($)shares | Jun. 30, 2018USD ($) | Mar. 31, 2018USD ($) | Sep. 30, 2019USD ($)$ / sharesshares | Sep. 30, 2018USD ($)shares | May 22, 2017USD ($)yr$ / sharesshares |
Stock Issued During Period, Value, Restricted Stock Award, Gross | $ 256,000 | $ 14,000 | $ 47,000 | $ 67,000 | $ 108,000 | ||||||||||
Proceeds from Issuance of Common Stock | $ 6,322,000 | $ 33,407,000 | |||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares | 1,000 | ||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 5,549 | 5,549 | |||||||||||||
Class of Warrants or Rights, Exercises in Period | shares | 0 | 0 | 0 | 0 | |||||||||||
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period | shares | 0 | 0 | 0 | ||||||||||||
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Expired In Period | shares | 859 | 0 | 859 | 0 | |||||||||||
The 2017 Loan Agreement [Member] | |||||||||||||||
Debt Issuance Costs, Net, Total | $ 790,000 | $ 790,000 | |||||||||||||
Amortization of Debt Discount (Premium) | $ 92,000 | $ 82,000 | $ 270,000 | $ 242,000 | |||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 2,220 | 2,220 | 2,220 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 950 | $ 950 | $ 950 | ||||||||||||
Warrants and Rights Outstanding, Term | 10 years | ||||||||||||||
Warrants and Rights Outstanding | $ 940,000 | ||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Dividend Rate [Member] | |||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | ||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Price Volatility [Member] | |||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.551 | ||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.0225 | ||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Term [Member] | |||||||||||||||
Warrants and Rights Outstanding, Measurement Input | yr | 10 | ||||||||||||||
Restricted Stock [Member] | |||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ 274 | ||||||||||||||
Stock Issued During Period, Value, Restricted Stock Award, Gross | $ 25,000 | ||||||||||||||
August 2019 ATM Facility [Member] | |||||||||||||||
Aggregate Offering Price | $ 6,760,000 | $ 6,760,000 | |||||||||||||
Stock Issued During Period, Shares, New Issues | shares | 1,004,171 | ||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ 6,322,000 | ||||||||||||||
November 2017 ATM Facility [Member] | |||||||||||||||
Aggregate Offering Price | $ 25,000,000 | $ 25,000,000 | |||||||||||||
Stock Issued During Period, Shares, New Issues | shares | 3,364 | 0 | 37 | 0 | 2,771 | ||||||||||
Proceeds From Issuance of Common Stock, Net | $ 1,318,000 | $ 11,000 | $ 11,000 | $ 1,194,000 | $ 1,194,000 | ||||||||||
December 2018 Offering [Member] | |||||||||||||||
Stock Issued During Period, Shares, New Issues | shares | 147,285 | ||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ 20,385,000 | ||||||||||||||
Proceeds from Issuance of Common Stock | $ 22,093,000 | ||||||||||||||
February 2018 Offering [Member] | |||||||||||||||
Stock Issued During Period, Shares, New Issues | shares | 115,000 | ||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ 32,214,000 | $ 32,214,000 | |||||||||||||
Stock Issued During Period, Value, Restricted Stock Award, Gross | 115,000 | ||||||||||||||
Proceeds from Issuance of Common Stock | $ 34,500,000 | $ 34,500,000 |
Note 9 - Common Stock - Summary
Note 9 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares | 9 Months Ended | |
Sep. 30, 2019 | May 22, 2017 | |
Shares Outstanding Under Warrants (in shares) | 5,549 | |
Vendors and Contractor Warrants, October 2014 Issuance [Member] | ||
Expiration Date | Oct. 13, 2019 | |
Exercise Price (in dollars per share) | $ 424 | |
Shares Outstanding Under Warrants (in shares) | 288 | |
Vendors and Contractor Warrants, November 2014 Issuance [Member] | ||
Expiration Date | Nov. 12, 2019 | |
Exercise Price (in dollars per share) | $ 424 | |
Shares Outstanding Under Warrants (in shares) | 125 | |
Employee Performance Bonus Warrants, February 2015 Issuance [Member] | ||
Expiration Date | Feb. 17, 2025 | |
Exercise Price (in dollars per share) | $ 400 | |
Shares Outstanding Under Warrants (in shares) | 754 | |
Contractor Warrants, March 2015 Issuance [Member] | ||
Expiration Date | Mar. 26, 2025 | |
Exercise Price (in dollars per share) | $ 272 | |
Shares Outstanding Under Warrants (in shares) | 14 | |
Contractor Warrants, May 2015 Issuance [Member] | ||
Expiration Date | May 12, 2025 | |
Exercise Price (in dollars per share) | $ 424 | |
Shares Outstanding Under Warrants (in shares) | 362 | |
May 2015 Issuance Second Contractor [Member] | ||
Expiration Date | May 17, 2020 | |
Exercise Price (in dollars per share) | $ 424 | |
Shares Outstanding Under Warrants (in shares) | 215 | |
Performance Bonus Warrants, December 2015 Issuance [Member] | ||
Expiration Date | Dec. 16, 2025 | |
Exercise Price (in dollars per share) | $ 560 | |
Shares Outstanding Under Warrants (in shares) | 267 | |
Distributor Warrants, April 2016 Issuance [Member] | ||
Expiration Date | Apr. 1, 2026 | |
Exercise Price (in dollars per share) | $ 608 | |
Shares Outstanding Under Warrants (in shares) | 250 | |
Contractor Warrants, May 2016 Issuance [Member] | ||
Expiration Date | May 11, 2021 | |
Exercise Price (in dollars per share) | $ 774 | |
Shares Outstanding Under Warrants (in shares) | 50 | |
June 2016 Issuance Related to 2016 Loan Agreement [Member] | ||
Expiration Date | Jun. 20, 2026 | |
Exercise Price (in dollars per share) | $ 498 | |
Shares Outstanding Under Warrants (in shares) | 1,004 | |
May 2017 Issuance Related to 2017 Loan Agreement [Member] | ||
Expiration Date | May 25, 2027 | |
Exercise Price (in dollars per share) | $ 950 | $ 950 |
Shares Outstanding Under Warrants (in shares) | 2,220 | 2,220 |
Note 10 - Summary of Stock Op_3
Note 10 - Summary of Stock Options (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||||||||||
Sep. 30, 2019 | Jul. 31, 2019 | Jun. 30, 2019 | Apr. 30, 2019 | Jan. 31, 2019 | Jun. 30, 2018 | Sep. 30, 2019 | Jun. 30, 2019 | Mar. 31, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018 | Jan. 01, 2019 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | 50,471 | 50,471 | 50,471 | 40,144 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ 298.99 | $ 298.99 | $ 298.99 | $ 456 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 8 years 109 days | 7 years 146 days | ||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross | 1,000 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance | 3,432 | 3,432 | 3,432 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 23,344 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% | |||||||||||
Share-based Payment Arrangement, Option [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | |||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 3,371,000 | $ 3,371,000 | $ 3,371,000 | |||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition | 2 years 73 days | |||||||||||||
Director [Member] | ||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross | 378 | 525 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 525 | |||||||||||||
Director [Member] | Restricted Stock [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 38.08 | $ 91 | ||||||||||||
Consultant [Member] | ||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross | 250 | |||||||||||||
Nonemployees [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% | |||||||||||
The 2006 Stock Option Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | 104 | 104 | 104 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 0 | 0 | 0 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ 992 | $ 992 | $ 992 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 3 years 109 days | |||||||||||||
The 2013 Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | 50,367 | 50,367 | 50,367 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ 297.56 | $ 297.56 | $ 297.56 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | 8 years 109 days | |||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance | 11,770 | 11,770 | 11,770 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 20,431 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 49,140 | 69,571 | ||||||||||||
Common Stock Shares Reserved For Future Issuance Percentage | 18.00% | 18.00% | 18.00% | |||||||||||
The 2013 Plan [Member] | Restricted Stock [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 3,625 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | 421 | 443 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period | 0 | |||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total | 0 | |||||||||||||
The 2013 Plan [Member] | Employees [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 2,375 | 23,069 | 20,544 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 301.17 | $ 117.86 | $ 364.98 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 0 | 0 | 0 | 0 | ||||||||||
The 2013 Plan [Member] | Nonemployees [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 0 | 100 | 275 | 2,123 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 283 | $ 121.82 | $ 241.69 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 0 | 0 | 0 | 0 | ||||||||||
The 2013 Plan [Member] | Underwritten Public Offering [Member] | ||||||||||||||
Minimum Gross Proceeds From Equity Offering Amount Used In Calculation Of Reserved Shares Percentage | $ 5,000,000 | |||||||||||||
2017 Employee Stock Purchase Plan [Member] | ||||||||||||||
Stock Issued During Period, Shares, Employee Stock Purchase Plans | 200 | 602 | 429 | |||||||||||
Shares Issued, Price Per Share | $ 3.75 | $ 32.30 | $ 3.75 | $ 32.30 | $ 79.88 | $ 3.75 | ||||||||
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares | 1,392 | 1,392 | 1,392 | |||||||||||
Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased | $ 13.16 | $ 75 | $ 2.12 | $ 100 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% | 0.00% |
Note 10 - Summary of Stock Op_4
Note 10 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2019USD ($)$ / sharesshares | Dec. 31, 2018$ / sharesshares | |
Options outstanding (in shares) | shares | 40,144 | |
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 456 | |
Options outstanding, weighted average remaining contractual term (Year) | 8 years 109 days | 7 years 146 days |
Options granted (in shares) | shares | 23,344 | |
Options granted, weighted average exercise price (in dollars per share) | $ / shares | $ 117.91 | |
Options exercised (in shares) | shares | ||
Options exercised, weighted average exercise price (in dollars per share) | $ / shares | ||
Options canceled (in shares) | shares | (13,017) | |
Options canceled, weighted average exercise price (in dollars per share) | $ / shares | $ 457.34 | |
Options outstanding (in shares) | shares | 50,471 | 40,144 |
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares | $ 298.99 | $ 456 |
Options outstanding, aggregate intrinsic value | $ | ||
Vested and exercisable and expected to vest, end of period (in shares) | shares | 48,506 | |
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share) | $ / shares | $ 302.18 | |
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year) | 8 years 109 days | |
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value | $ | ||
Vested and exercisable, end of period (in shares) | shares | 21,169 | |
Vested and exercisable, end of period, weighted average exercise price (in dollars per share) | $ / shares | $ 397.45 | |
Vested and exercisable, end of period, weighted average remaining contractual term (Year) | 7 years 146 days | |
Vested and exercisable, end of period, aggregate intrinsic value | $ |
Note 10 - Summary of Stock Op_5
Note 10 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details) | 9 Months Ended |
Sep. 30, 2019$ / sharesshares | |
Options outstanding, number (in shares) | shares | 50,471 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 298.99 |
Options outstanding, weighted average remaining contractual term (Year) | 8 years 109 days |
Options exercisable, number exercisable (in shares) | shares | 21,169 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 397.45 |
Range One [Member] | |
Exercise price range, lower limit (in dollars per share) | 38 |
Exercise price range, upper limit (in dollars per share) | $ 58 |
Options outstanding, number (in shares) | shares | 1,650 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 55.42 |
Options outstanding, weighted average remaining contractual term (Year) | 9 years 255 days |
Options exercisable, number exercisable (in shares) | shares | |
Range Two [Member] | |
Exercise price range, lower limit (in dollars per share) | $ 100 |
Exercise price range, upper limit (in dollars per share) | $ 197 |
Options outstanding, number (in shares) | shares | 25,496 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 138.25 |
Options outstanding, weighted average remaining contractual term (Year) | 9 years 36 days |
Options exercisable, number exercisable (in shares) | shares | 6,839 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 148.08 |
Range Three [Member] | |
Exercise price range, lower limit (in dollars per share) | 202 |
Exercise price range, upper limit (in dollars per share) | $ 283 |
Options outstanding, number (in shares) | shares | 775 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 252.06 |
Options outstanding, weighted average remaining contractual term (Year) | 8 years 109 days |
Options exercisable, number exercisable (in shares) | shares | 305 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 258.36 |
Range Four [Member] | |
Exercise price range, lower limit (in dollars per share) | 311 |
Exercise price range, upper limit (in dollars per share) | $ 382 |
Options outstanding, number (in shares) | shares | 4,377 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 357.96 |
Options outstanding, weighted average remaining contractual term (Year) | 8 years 36 days |
Options exercisable, number exercisable (in shares) | shares | 2,318 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 360.44 |
Range Five [Member] | |
Exercise price range, lower limit (in dollars per share) | 430 |
Exercise price range, upper limit (in dollars per share) | $ 497 |
Options outstanding, number (in shares) | shares | 8,908 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 452.58 |
Options outstanding, weighted average remaining contractual term (Year) | 7 years 255 days |
Options exercisable, number exercisable (in shares) | shares | 4,576 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 454.70 |
Range Six [Member] | |
Exercise price range, lower limit (in dollars per share) | 501 |
Exercise price range, upper limit (in dollars per share) | $ 567 |
Options outstanding, number (in shares) | shares | 4,594 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 536.63 |
Options outstanding, weighted average remaining contractual term (Year) | 6 years 328 days |
Options exercisable, number exercisable (in shares) | shares | 3,126 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 536.17 |
Range Seven [Member] | |
Exercise price range, lower limit (in dollars per share) | 600 |
Exercise price range, upper limit (in dollars per share) | $ 661 |
Options outstanding, number (in shares) | shares | 2,397 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 601.91 |
Options outstanding, weighted average remaining contractual term (Year) | 5 years 328 days |
Options exercisable, number exercisable (in shares) | shares | 2,236 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 601.42 |
Range Eight [Member] | |
Exercise price range, lower limit (in dollars per share) | 700 |
Exercise price range, upper limit (in dollars per share) | $ 792 |
Options outstanding, number (in shares) | shares | 2,170 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 769.23 |
Options outstanding, weighted average remaining contractual term (Year) | 6 years 109 days |
Options exercisable, number exercisable (in shares) | shares | 1,665 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 769.86 |
Range Nine [Member] | |
Exercise price range, lower limit (in dollars per share) | 992 |
Exercise price range, upper limit (in dollars per share) | $ 992 |
Options outstanding, number (in shares) | shares | 104 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 992 |
Options outstanding, weighted average remaining contractual term (Year) | 3 years 109 days |
Options exercisable, number exercisable (in shares) | shares | 104 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 992 |
Note 10 - Summary of Stock Op_6
Note 10 - Summary of Stock Options - Valuation Assumption for Employee Stock Purchase Plan (Details) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Expected term (Year) | 5 years | 5 years | 5 years | |
Average volatility | 70.00% | 73.00% | 73.00% | |
Risk-free interest rate | 2.86% | 2.49% | 2.67% | |
Dividend yield | 0.00% | 0.00% | 0.00% | |
2017 Employee Stock Purchase Plan [Member] | ||||
Expected term (Year) | 91 days | 91 days | 91 days | 91 days |
Average volatility | 98.00% | 67.00% | 84.00% | 67.00% |
Risk-free interest rate | 2.21% | 1.93% | 2.40% | 1.71% |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% |
Note 10 - Summary of Stock Op_7
Note 10 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Expected term (Year) | 5 years | 5 years | 5 years | |
Average volatility | 70.00% | 73.00% | 73.00% | |
Risk-free interest rate | 2.86% | 2.49% | 2.67% | |
Dividend yield | 0.00% | 0.00% | 0.00% | |
Nonemployees [Member] | ||||
Expected term (Year) | 10 years | 5 years | 10 years | |
Average volatility | 66.00% | 73.00% | 66.00% | |
Risk-free interest rate | 3.04% | 2.49% | 3.04% | |
Dividend yield | 0.00% | 0.00% | 0.00% |
Note 10 - Summary of Stock Op_8
Note 10 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | |
Stock-based compensation expense | $ 517 | $ 765 | $ 1,634 | $ 2,294 |
Cost of Sales [Member] | ||||
Stock-based compensation expense | 25 | 19 | 91 | 47 |
Research and Development Expense [Member] | ||||
Stock-based compensation expense | 41 | 79 | 134 | 266 |
Selling, General and Administrative Expenses [Member] | ||||
Stock-based compensation expense | $ 451 | $ 667 | $ 1,409 | $ 1,981 |
Note 11 - Income Taxes (Details
Note 11 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended |
Sep. 30, 2019 | Sep. 30, 2019 | Dec. 31, 2019 | |
Income Tax Expense (Benefit), Total | $ 0 | ||
Effective Income Tax Rate Reconciliation, Percent, Total | 0.00% | 0.00% | |
Forecast [Member] | |||
Effective Income Tax Rate Reconciliation, Percent, Total | 0.00% |
Note 12 - Related Party Trans_2
Note 12 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($) | 3 Months Ended | 9 Months Ended | 120 Months Ended | |||
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Dec. 31, 2018 | |
Stock Issued During Period, Shares, New Issues | 375 | |||||
Related Party Transaction, Amounts of Transaction | $ 720,000 | $ 3,015,000 | $ 3,853,000 | $ 8,613,000 | ||
Accounts Payable, Related Parties, Current | $ 456,000 | $ 456,000 | $ 456,000 | $ 960,000 |
Note 13 - Restructuring Costs (
Note 13 - Restructuring Costs (Details Textual) | 1 Months Ended | 3 Months Ended | 9 Months Ended | ||
Jan. 31, 2019USD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2018USD ($) | Sep. 30, 2019USD ($) | Sep. 30, 2018USD ($) | |
Restructuring and Related Cost, Number of Positions Eliminated | 40 | ||||
Restructuring Charges, Total | $ 742,000 | $ 742,000 |